Presentation is loading. Please wait.

Presentation is loading. Please wait.

What to include? Should EDCTP-2 be expanded to other fields? Marja Esveld, 29 September 2010.

Similar presentations


Presentation on theme: "What to include? Should EDCTP-2 be expanded to other fields? Marja Esveld, 29 September 2010."— Presentation transcript:

1 What to include? Should EDCTP-2 be expanded to other fields? Marja Esveld, 29 September 2010

2 Current mandate of EDCTP EDCTP aims to accelerate the development of new or improved drugs, vaccines and microbicides against HIV/AIDS, malaria and tuberculosis, with a focus on phase II and III clinical trials in sub-Saharan Africa.

3 Leading Causes of Mortality and Burden of Disease World, 2004 % Ischaemic heart disease 12.2 Cerebrovascular disease 9.7 Lower respiratory infections 7.1 COPD 5.1 Diarrhoeal diseases 3.7 HIV/AIDS 3.5 Tuberculosis 2.5 Trachea, bronchus, lung cancers 2.3 Road traffic accidents 2.2 Prematurity, low birth weight 2.0 % Lower respiratory infections 6.2 Diarrhoeal diseases 4.8 Depression4.3 Ischaemic heart disease 4.1 HIV/AIDS3.8 Cerebrovascular disease 3.1 Prematurity, low birth weight 2.9 Birth asphyxia, birth trauma 2.7 Road traffic accidents 2.7 Neonatal infections and other 2.7 MortalityDALYs* * Disabilty adjusted life years

4 Burden of disease by broad cause group and region, 2004

5 Lower respiratory infections Diarrhoeal diseases HIV/AIDS Malaria Prematurity and low birth weight Neonatal infections and other Birth asphyxia and birth trauma Unipolar depressive disorders Ischaemic heart disease Tuberculosis Burden of disease in low income countries, 2004 Per cent of total DALYs DALYs (millions)

6 Lower respiratory infections Diarrhoeal diseases HIV/AIDS Malaria Prematurity and low birth weight Neonatal infections and other Birth asphyxia and birth trauma Unipolar depressive disorders Ischaemic heart disease Tuberculosis Need for new or improved products for prevention and control Per cent of total DALYs DALYs (millions)

7 Global funding for Neglected Disease Research Source: G-Finder %Funding US$ (*1000) HIV/Aids 1,083,0181,154,88239,4 Malaria 468,449541,74618,3 TB 410,428445,92715,1 Kinetoplastids 125,122139,2074,7 Diarrhoeal diseases 113,889132,1984,5 Dengue 82,01312,7524,3 Bact.pneumonia/men. 32,51790,8443,1 Helminth infections 51,59166,8372,3 Salmonella infections 9,11739,4861,3

8 Reasons to expand Diseases Double neglected diseases cause high morbidity Clear funding gap Low hanging fruits Efficiencies: some interventions could serve more diseases Geographical area Capacity building needs in almost all other regions Aids/HIV and TB epidemics outside Sub Sahara Africa (including Eastern Europe!) Some NTDs have focus outside Africa (Chagas, Dengue) Efficiencies: some interventions could serve more regions or there may be a small commercial market

9 Reasons to expand Type of products Diagnostics key to effective (and efficient) treatment Potential impact of non-medical products (ie insecticides) Position in pipeline Phase I studies needed to ensure innovation Phase IV and access studies needed to enhance uptake and optimal use Expanded pipeline allows for more strategic planning

10 Reasons NOT to expand Challenge to define scope / set priorities WHO definition for NTDs include 10 diseases Do we include vector control? Need for products vs other preventive interventions (ie sanitation) Need for additional funding Need to expand expertise in SAC and other EDCTP governance bodies Additional programmes (FP7/8, global programmes) may cover research

11 Thank you!


Download ppt "What to include? Should EDCTP-2 be expanded to other fields? Marja Esveld, 29 September 2010."

Similar presentations


Ads by Google